On March 11, the European Commission (EC) granted marketing authorization for imetelstat (RYTELO®) as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low, or intermediate-risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. 

For more information, read the Geron press release.

Posted on 3/13/25